Combination Therapy with Dapagliflozin and Saxagliptin prevents diabetes-induced inflammation and organ injury by targeting the Nirp3/ASC inflammasome

Project: Other project

StatusFinished
Effective start/end date12/17/156/30/18

Funding

  • AstraZeneca LP: $128,380.00